Radiotherapy & Oncology
Volume 87, Issue 3 , Pages 326-330 , June 2008

Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study

  • Katsuyuki Karasawa

      Affiliations

    • Department of Radiology, Tokyo Metropolitan Komagome Hospital, Japan
    • Corresponding Author InformationCorresponding author. Katsuyuki Karasawa, Department of Radiology, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
    • ,
  • Makoto Sunamura

      Affiliations

    • Department of Surgery, Tohoku University School of Medicine, Japan
    • ,
  • Atsutake Okamoto

      Affiliations

    • Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
    • ,
  • Kenji Nemoto

      Affiliations

    • Department of Radiology, Tohoku University School of Medicine, Japan
    • ,
  • Seiki Matsuno

      Affiliations

    • Department of Surgery, Tohoku University School of Medicine, Japan
    • ,
  • Yasumasa Nishimura

      Affiliations

    • Department of Radiation Oncology, Kinki University School of Medicine, Japan
    • ,
  • Yuta Shibamoto

      Affiliations

    • Department of Radiology, Nagoya City University School of Medicine, Japan

Received 22 June 2007 ,Revised 9 February 2008 ,Accepted 9 February 2008.

References 

  1. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29–34
  2. Ceha HM, van Tienhoven G, Gouma DJ, et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer. 2000;89:2222–2229
  3. Coleman CN, Buswell L, Noll L, Riese N, Rose MA. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 1992;22:565–568
  4. Coleman CN. Conference summary: the ninth international conference on the chemical modifiers of cancer treatment. Br J Cancer Suppl. 1996;27:S297–S304
  5. Crane CH, Antolak JA, Rosen II, et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer. 2001;30:123–132
  6. Eschwege F, Sancho-Garnier H, Chassagne D, et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1997;39:273–274
  7. Furuse J, Kinoshita T, Kawashima M, et al. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer. 2003;97:1346–1352
  8. Garton GR, Gunderson LL, Nagorney DM, et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 1993;27:1153–1157
  9. Gunderson LL, Nagorney DM, Martenson JA, et al. External beam plus intraoperative irradiation for gastrointestinal cancers. World J Surg. 1995;19:191–197
  10. Kuno Y, Shinomiya N. PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction. Apoptosis. 2000;5:69–77
  11. Lee DJ, Cosmatos D, Marcial VA, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1995;32:883–885
  12. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003;57:98–104
  13. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202–4208
  14. Mohiuddin M, Cantor RJ, Biermann W, Weiss SM, Barbot D, Rosato FE. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1988;14:79–84
  15. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys. 1997;39:39–49
  16. Okamoto A, Matsumoto G, Tsuruta K, et al. Intraoperative radiation therapy for pancreatic adenocarcinoma: the Komagome hospital experience. Pancreas. 2004;28:296–300
  17. Overgaard J, Hansen HS, Andersen AP, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys. 1989;16:1065–1068
  18. Overgaard J. Sensitization of hypoxic tumour cells – clinical experience. Int J Radiat Biol. 1989;56:801–811
  19. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46:135–146
  20. Rubin P, Williams JP, Okunieff P, et al. Statement of the clinical oncologic problem. In:  Rubin P editors. Clinical oncology: a multidisciplinary approach for physicians and students. 8th ed.. Philadelphia: WB Saunders; 2001;p. 1–31
  21. Shibamoto Y, Kubota T, Kishii K, et al. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol. 2000;56:265–270
  22. Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg. 1984;200:289–296
  23. Sunamura M, Matsuno S, Okamoto A, et al. Phase I clinical trial for the effect of a radiosensitizer, PR-350 (doranidazole) combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. Suizo. 2003;18–23
  24. Sunamura M, Karasawa K, Okamoto A, et al. Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas. 2004;28:330–334

☆ Presented at 13th ECCO, held October 30th to November 3rd, 2005, Paris.

PII: S0167-8140(08)00101-1

doi: 10.1016/j.radonc.2008.02.007

Radiotherapy & Oncology
Volume 87, Issue 3 , Pages 326-330 , June 2008

Article Tools

* Image Usage & Resolution